Gastric Cancer Drugs Market by Therapeutic Class (Biologics, Chemotherapy, Immunotherapy), Treatment Line (First Line, Second Line, Third Line Or Later), Route Of Administration, Dosage Form, Therapy Type, Distribution Channel - Global Forecast 2025-2032
Description
The Gastric Cancer Drugs Market was valued at USD 4.06 billion in 2024 and is projected to grow to USD 4.31 billion in 2025, with a CAGR of 6.32%, reaching USD 6.63 billion by 2032.
A concise strategic framing of the multifaceted forces reshaping clinical practice, innovation and commercial approaches in gastric cancer therapeutics
Gastric cancer remains a major global oncology challenge characterized by heterogeneity in tumor biology, variable clinical presentations, and disparate outcomes across geographies. Advances in molecular profiling and immuno-oncology have reshaped clinical paradigms over the past decade, moving care away from one-size-fits-all cytotoxic approaches toward biomarker-driven therapies, antibody–drug conjugates, and immune-modulating agents. Concurrently, health systems and payers are demanding clearer evidence of clinical benefit and economic value, which in turn shapes development priorities and commercialization tactics.
Against this backdrop, the therapeutic landscape is defined by the interplay of scientific innovation, regulatory evolution, and market dynamics. Diagnostic stratification for HER2 expression, PD-L1 status, and microsatellite instability has become central to patient selection and trial design, while next-generation targeted agents and combination regimens are expanding options for previously refractory populations. With these shifts, stakeholders across the value chain-including innovators, contract manufacturers, diagnostics companies, and payers-face a rapidly changing environment that requires strategic agility. This executive summary synthesizes the most consequential trends, segmentation insights, regional dynamics, and recommended actions that leaders should consider to navigate near-term disruptions and long-term transformation in gastric cancer therapeutics.
How advances in molecular targeting, immuno-oncology and adaptive development models are rewriting clinical pathways and commercial playbooks in gastric oncology
The landscape for gastric cancer therapies is undergoing transformative shifts driven by breakthroughs in targeted modalities, the maturation of immuno-oncology, and a growing emphasis on precision diagnostics. Therapeutic innovation is no longer incremental; the rise of antibody–drug conjugates and novel targeted inhibitors has created new lines of clinical inquiry and altered standards of care. As clinical evidence accumulates, combination regimens pairing checkpoint inhibitors with targeted agents or cytotoxics are redefining response expectations and expanding indications for subpopulations previously underserved by conventional chemotherapy.
Operationally, these scientific advances are catalyzing complementary changes in clinical trial design, regulatory engagement, and commercial planning. Adaptive trial architectures and biomarker-enriched cohorts are shortening development timelines and improving signal detection, while regulatory authorities are increasingly amenable to accelerated pathways when compelling translational data exist. At the same time, there is a pronounced shift in delivery models: oral targeted therapies and subcutaneous formulations are improving patient convenience and reducing infusion burdens, while hospital and outpatient infusion centers are adapting to a higher volume of complex biologic administrations. Finally, stakeholders are confronting the economic implications of durable but high-cost therapies, prompting earlier payer dialogue, value-based contracting pilots, and real-world evidence initiatives to demonstrate sustained benefit in heterogeneous patient populations.
The aggregate effect of tariff recalibrations on supply chain resilience, sourcing strategies and launch readiness for gastric cancer therapeutics
In 2025, cumulative tariff adjustments and trade policy shifts have amplified cost and supply chain complexity for pharmaceutical stakeholders engaged in gastric cancer drug development and distribution. Tariff changes affecting active pharmaceutical ingredients, biologics components, and finished injectable products have increased the attention on sourcing strategies and the resilience of supply networks. As a result, manufacturers and contract development and manufacturing organizations are reassessing supplier footprints, bringing certain critical processes closer to commercial markets or qualified alternate suppliers to mitigate exposure to tariff volatility and cross-border delays.
These trade-driven pressures have practical implications for procurement, inventory strategy, and launch sequencing. Firms are prioritizing dual-sourcing for key raw materials and qualifying regional manufacturing capabilities to preserve continuity of supply for high-priority oncology agents. Moreover, contracting teams are renegotiating long-term agreements with logistics providers to secure capacity and limit the pass-through of tariff-related costs. In parallel, regulatory affairs and quality teams are intensifying coordination to expedite site transfers and meet regional regulatory expectations when manufacturing footprints are adjusted. Collectively, these measures reflect a strategic pivot: companies are balancing cost management against the imperative to sustain on-time clinical supply and commercial availability for life-saving therapies.
Strategic segmentation analysis linking therapeutic class, treatment line, distribution, administration route, dosage forms and therapy type to guide development and commercialization
A nuanced understanding of market segmentation is essential to designing development portfolios and commercialization strategies that align with clinical need and payer expectations. Based on therapeutic class, the market comprises Biologics, Chemotherapy, Immunotherapy, and Targeted Therapy; within Biologics there is a focus on Cytokines and Monoclonal Antibodies, while Chemotherapy continues to include Fluoropyrimidines, Platinum-Based Agents, and Taxanes; Immunotherapy divides into Cancer Vaccines and Checkpoint Inhibitors, and Targeted Therapy emphasizes Her2 Inhibitors and Vegf Inhibitors. These class distinctions influence clinical trial endpoints, regulatory pathways, manufacturing complexity, and pricing dynamics, with biologics and targeted agents typically demanding differentiated distribution and cold-chain logistics compared with oral small molecules.
When viewed through the lens of treatment line-first line, second line, and third line or later-the therapeutic strategy and commercial value proposition shift markedly. First-line regimens prioritize broad efficacy and safety to capture larger patient populations, while later-line therapies frequently target biomarker-defined subsets and emphasize depth of response or quality-of-life improvements. Distribution channel segmentation between hospital pharmacies and retail pharmacies highlights divergent stakeholder interactions and reimbursement considerations; hospital settings increasingly manage complex infusions and combination regimens, whereas retail channels support oral and chronic maintenance therapies. Route of administration further differentiates product positioning: intravenous therapies remain central to many advanced regimens, oral agents enable outpatient management and adherence strategies, and subcutaneous formulations offer opportunities to reduce administration time and improve patient convenience.
Dosage form considerations-capsules, lyophilized powder, pre-filled syringes, and tablets-drive manufacturing and packaging decisions that impact time-to-market and handling requirements. Finally, therapy type distinctions between combination therapy and monotherapy underpin clinical trial design and commercial messaging, because combination regimens require coordinated co-development and often complex pricing and reimbursement negotiations. Integrating these segmentation dimensions allows stakeholders to target development investments, optimize clinical trial populations, and align channel strategies with patient care pathways.
How differing epidemiology, regulatory systems and payer dynamics across major regions shape access pathways, trial activity and commercialization strategies in gastric oncology
Regional dynamics in gastric cancer therapeutics are driven by epidemiology, regulatory frameworks, payer practices, and clinical research ecosystems. In the Americas, regulatory pathways and payer negotiations shape accelerated adoption for therapies with robust clinical endpoints, and the presence of large oncology networks and clinical trial infrastructures facilitates rapid enrollment for global studies. Meanwhile, pricing scrutiny and value-based purchasing experiments are prompting earlier evidence generation focused on long-term outcomes and real-world effectiveness to support reimbursement discussions.
In Europe, the Middle East and Africa region, heterogeneity across national health technology assessment processes and reimbursement timelines creates a layered market access environment. Stakeholders must tailor single-country access strategies while leveraging regional centers of excellence for clinical trials and real-world evidence collection. Regulatory harmonization efforts in certain subregions coexist with diverse budgetary constraints, requiring differentiated pricing and patient access programs. In the Asia-Pacific region, higher incidence rates in several countries are driving strong clinical interest and expansive trial activity, and local manufacturing capabilities and biosimilar adoption trends are reshaping cost dynamics. Moreover, regulatory modernization and faster local approvals in specific markets are encouraging earlier market entry strategies for companies willing to invest in region-specific data packages. Across all regions, cross-border collaboration on diagnostics, trial networks, and supply chain contingency planning remains critical to ensure timely patient access to new therapies.
Competitive and partnership strategies embraced by innovators, specialty manufacturers and diagnostics collaborators to secure clinical differentiation and market access
Companies operating in the gastric cancer space are deploying diverse strategies to capture clinical and commercial advantage, with an emphasis on innovation, partnership, and operational excellence. Innovative biopharmaceutical companies are prioritizing late-stage assets that demonstrate meaningful survival benefit or durable responses in biomarker-defined populations, and they are increasingly pursuing combination approaches to deepen and extend responses. Biotech firms with niche expertise in antibody engineering, payload optimization for conjugates, and small-molecule selectivity are attractive partners for larger firms seeking to augment pipelines and accelerate translational milestones.
At the same time, contract development and manufacturing organizations and specialty pharmaceutical companies are expanding capacities for biologics, aseptic fill-finish, and complex packaging to support the growing biologics and ADC segments. Strategic alliances between developers and diagnostic firms are becoming more common as companion diagnostics are essential for precise patient selection and label expansion. Additionally, companies are investing in real-world evidence generation and health economics teams to support payer negotiations and to demonstrate comparative effectiveness over existing standards. Across these efforts, successful organizations are those that integrate clinical development with commercial foresight, ensure supply chain robustness, and cultivate payer relationships early to reduce time-to-access once regulatory approvals are secured.
A pragmatic and coordinated set of strategic imperatives to align clinical development, supply resilience and commercial readiness for leaders in gastric oncology
Industry leaders should adopt a multi-dimensional strategic playbook that balances scientific ambition with pragmatic operational execution. First, align early development programs with clear biomarker strategies and companion diagnostic plans to increase the probability of regulatory success and payer acceptance; integrating diagnostic development into pivotal trials reduces downstream barriers to access. Second, prioritize supply chain redundancy for critical biologic components and finished products, including dual-sourcing, regional manufacturing options, and validated contingency plans to mitigate tariff-driven disruptions and logistic volatility.
Third, design commercial models that reflect route-of-administration preferences and distribution realities, investing in hub-and-spoke service models that support hospital-administered infusions while enabling retail access for oral maintenance therapies. Fourth, invest in robust real-world evidence generation to demonstrate long-term value and to support innovative contracting models with payers, including outcomes-based agreements where feasible. Fifth, actively pursue strategic partnerships-whether licensing, co-development, or manufacturing alliances-to accelerate development timelines and broaden market reach while sharing commercial risk. By implementing these actions in a coordinated manner, leaders can improve launch readiness, optimize ROI on development investments, and enhance patient access to transformative therapies.
A rigorous mixed-methods approach combining expert interviews, literature synthesis and data triangulation to produce validated and actionable intelligence
The research methodology underpinning this executive summary combines qualitative expert insight with systematic synthesis of primary and secondary inputs to ensure robust, actionable conclusions. Primary research consisted of structured interviews with oncologists, clinical trial investigators, regulatory affairs specialists, payers, and supply chain leaders engaged in gastric cancer therapeutics; these interviews provided contemporary perspectives on clinical adoption patterns, reimbursement expectations, and operational constraints. Secondary research incorporated peer-reviewed literature, regulatory guidance documents, clinical trial registries, and established therapeutic guidelines to validate mechanistic understandings and to contextualize trial outcomes and approval precedents.
Data triangulation was applied to reconcile divergent views across stakeholders and to identify consistent themes that merit strategic attention. Where possible, case examples from recent approvals and payer decisions were used to illustrate practical implications for commercialization and evidence generation, without relying on proprietary market estimates. The synthesis emphasized cross-functional alignment-linking clinical trial design to diagnostic strategy, manufacturing strategy, and payer engagement-to provide a holistic framework that organizations can operationalize. Finally, quality assurance procedures, including expert review and iterative validation with clinical advisors, were employed to ensure the accuracy and relevance of the findings presented here.
A concise synthesis of pivotal scientific, operational and market imperatives that will determine which therapies realize their clinical and commercial potential in gastric cancer
In summary, the gastric cancer therapeutic arena is transitioning into an era defined by precision approaches, more complex combination strategies, and heightened expectations for demonstrable value. Scientific advances are expanding treatment options, especially for biomarker-defined subgroups, while commercial success will increasingly depend on early integration of diagnostic strategies, resilient supply chains, and compelling real-world evidence to support reimbursement. Trade and policy developments, including tariff adjustments, have highlighted the need for geographic diversification of manufacturing and flexible sourcing to preserve clinical supply and launch timelines.
Looking ahead, organizations that invest in biomarker-driven development, cultivate strategic partnerships, and proactively engage payers with rigorous outcomes data will be best positioned to translate clinical innovation into sustained patient impact. The path to durable success in gastric oncology requires coordinated execution across R&D, regulatory affairs, manufacturing, and commercial functions, with an unwavering focus on meeting patient needs and demonstrating the value of new therapies in real-world settings.
Please Note: PDF & Excel + Online Access - 1 Year
A concise strategic framing of the multifaceted forces reshaping clinical practice, innovation and commercial approaches in gastric cancer therapeutics
Gastric cancer remains a major global oncology challenge characterized by heterogeneity in tumor biology, variable clinical presentations, and disparate outcomes across geographies. Advances in molecular profiling and immuno-oncology have reshaped clinical paradigms over the past decade, moving care away from one-size-fits-all cytotoxic approaches toward biomarker-driven therapies, antibody–drug conjugates, and immune-modulating agents. Concurrently, health systems and payers are demanding clearer evidence of clinical benefit and economic value, which in turn shapes development priorities and commercialization tactics.
Against this backdrop, the therapeutic landscape is defined by the interplay of scientific innovation, regulatory evolution, and market dynamics. Diagnostic stratification for HER2 expression, PD-L1 status, and microsatellite instability has become central to patient selection and trial design, while next-generation targeted agents and combination regimens are expanding options for previously refractory populations. With these shifts, stakeholders across the value chain-including innovators, contract manufacturers, diagnostics companies, and payers-face a rapidly changing environment that requires strategic agility. This executive summary synthesizes the most consequential trends, segmentation insights, regional dynamics, and recommended actions that leaders should consider to navigate near-term disruptions and long-term transformation in gastric cancer therapeutics.
How advances in molecular targeting, immuno-oncology and adaptive development models are rewriting clinical pathways and commercial playbooks in gastric oncology
The landscape for gastric cancer therapies is undergoing transformative shifts driven by breakthroughs in targeted modalities, the maturation of immuno-oncology, and a growing emphasis on precision diagnostics. Therapeutic innovation is no longer incremental; the rise of antibody–drug conjugates and novel targeted inhibitors has created new lines of clinical inquiry and altered standards of care. As clinical evidence accumulates, combination regimens pairing checkpoint inhibitors with targeted agents or cytotoxics are redefining response expectations and expanding indications for subpopulations previously underserved by conventional chemotherapy.
Operationally, these scientific advances are catalyzing complementary changes in clinical trial design, regulatory engagement, and commercial planning. Adaptive trial architectures and biomarker-enriched cohorts are shortening development timelines and improving signal detection, while regulatory authorities are increasingly amenable to accelerated pathways when compelling translational data exist. At the same time, there is a pronounced shift in delivery models: oral targeted therapies and subcutaneous formulations are improving patient convenience and reducing infusion burdens, while hospital and outpatient infusion centers are adapting to a higher volume of complex biologic administrations. Finally, stakeholders are confronting the economic implications of durable but high-cost therapies, prompting earlier payer dialogue, value-based contracting pilots, and real-world evidence initiatives to demonstrate sustained benefit in heterogeneous patient populations.
The aggregate effect of tariff recalibrations on supply chain resilience, sourcing strategies and launch readiness for gastric cancer therapeutics
In 2025, cumulative tariff adjustments and trade policy shifts have amplified cost and supply chain complexity for pharmaceutical stakeholders engaged in gastric cancer drug development and distribution. Tariff changes affecting active pharmaceutical ingredients, biologics components, and finished injectable products have increased the attention on sourcing strategies and the resilience of supply networks. As a result, manufacturers and contract development and manufacturing organizations are reassessing supplier footprints, bringing certain critical processes closer to commercial markets or qualified alternate suppliers to mitigate exposure to tariff volatility and cross-border delays.
These trade-driven pressures have practical implications for procurement, inventory strategy, and launch sequencing. Firms are prioritizing dual-sourcing for key raw materials and qualifying regional manufacturing capabilities to preserve continuity of supply for high-priority oncology agents. Moreover, contracting teams are renegotiating long-term agreements with logistics providers to secure capacity and limit the pass-through of tariff-related costs. In parallel, regulatory affairs and quality teams are intensifying coordination to expedite site transfers and meet regional regulatory expectations when manufacturing footprints are adjusted. Collectively, these measures reflect a strategic pivot: companies are balancing cost management against the imperative to sustain on-time clinical supply and commercial availability for life-saving therapies.
Strategic segmentation analysis linking therapeutic class, treatment line, distribution, administration route, dosage forms and therapy type to guide development and commercialization
A nuanced understanding of market segmentation is essential to designing development portfolios and commercialization strategies that align with clinical need and payer expectations. Based on therapeutic class, the market comprises Biologics, Chemotherapy, Immunotherapy, and Targeted Therapy; within Biologics there is a focus on Cytokines and Monoclonal Antibodies, while Chemotherapy continues to include Fluoropyrimidines, Platinum-Based Agents, and Taxanes; Immunotherapy divides into Cancer Vaccines and Checkpoint Inhibitors, and Targeted Therapy emphasizes Her2 Inhibitors and Vegf Inhibitors. These class distinctions influence clinical trial endpoints, regulatory pathways, manufacturing complexity, and pricing dynamics, with biologics and targeted agents typically demanding differentiated distribution and cold-chain logistics compared with oral small molecules.
When viewed through the lens of treatment line-first line, second line, and third line or later-the therapeutic strategy and commercial value proposition shift markedly. First-line regimens prioritize broad efficacy and safety to capture larger patient populations, while later-line therapies frequently target biomarker-defined subsets and emphasize depth of response or quality-of-life improvements. Distribution channel segmentation between hospital pharmacies and retail pharmacies highlights divergent stakeholder interactions and reimbursement considerations; hospital settings increasingly manage complex infusions and combination regimens, whereas retail channels support oral and chronic maintenance therapies. Route of administration further differentiates product positioning: intravenous therapies remain central to many advanced regimens, oral agents enable outpatient management and adherence strategies, and subcutaneous formulations offer opportunities to reduce administration time and improve patient convenience.
Dosage form considerations-capsules, lyophilized powder, pre-filled syringes, and tablets-drive manufacturing and packaging decisions that impact time-to-market and handling requirements. Finally, therapy type distinctions between combination therapy and monotherapy underpin clinical trial design and commercial messaging, because combination regimens require coordinated co-development and often complex pricing and reimbursement negotiations. Integrating these segmentation dimensions allows stakeholders to target development investments, optimize clinical trial populations, and align channel strategies with patient care pathways.
How differing epidemiology, regulatory systems and payer dynamics across major regions shape access pathways, trial activity and commercialization strategies in gastric oncology
Regional dynamics in gastric cancer therapeutics are driven by epidemiology, regulatory frameworks, payer practices, and clinical research ecosystems. In the Americas, regulatory pathways and payer negotiations shape accelerated adoption for therapies with robust clinical endpoints, and the presence of large oncology networks and clinical trial infrastructures facilitates rapid enrollment for global studies. Meanwhile, pricing scrutiny and value-based purchasing experiments are prompting earlier evidence generation focused on long-term outcomes and real-world effectiveness to support reimbursement discussions.
In Europe, the Middle East and Africa region, heterogeneity across national health technology assessment processes and reimbursement timelines creates a layered market access environment. Stakeholders must tailor single-country access strategies while leveraging regional centers of excellence for clinical trials and real-world evidence collection. Regulatory harmonization efforts in certain subregions coexist with diverse budgetary constraints, requiring differentiated pricing and patient access programs. In the Asia-Pacific region, higher incidence rates in several countries are driving strong clinical interest and expansive trial activity, and local manufacturing capabilities and biosimilar adoption trends are reshaping cost dynamics. Moreover, regulatory modernization and faster local approvals in specific markets are encouraging earlier market entry strategies for companies willing to invest in region-specific data packages. Across all regions, cross-border collaboration on diagnostics, trial networks, and supply chain contingency planning remains critical to ensure timely patient access to new therapies.
Competitive and partnership strategies embraced by innovators, specialty manufacturers and diagnostics collaborators to secure clinical differentiation and market access
Companies operating in the gastric cancer space are deploying diverse strategies to capture clinical and commercial advantage, with an emphasis on innovation, partnership, and operational excellence. Innovative biopharmaceutical companies are prioritizing late-stage assets that demonstrate meaningful survival benefit or durable responses in biomarker-defined populations, and they are increasingly pursuing combination approaches to deepen and extend responses. Biotech firms with niche expertise in antibody engineering, payload optimization for conjugates, and small-molecule selectivity are attractive partners for larger firms seeking to augment pipelines and accelerate translational milestones.
At the same time, contract development and manufacturing organizations and specialty pharmaceutical companies are expanding capacities for biologics, aseptic fill-finish, and complex packaging to support the growing biologics and ADC segments. Strategic alliances between developers and diagnostic firms are becoming more common as companion diagnostics are essential for precise patient selection and label expansion. Additionally, companies are investing in real-world evidence generation and health economics teams to support payer negotiations and to demonstrate comparative effectiveness over existing standards. Across these efforts, successful organizations are those that integrate clinical development with commercial foresight, ensure supply chain robustness, and cultivate payer relationships early to reduce time-to-access once regulatory approvals are secured.
A pragmatic and coordinated set of strategic imperatives to align clinical development, supply resilience and commercial readiness for leaders in gastric oncology
Industry leaders should adopt a multi-dimensional strategic playbook that balances scientific ambition with pragmatic operational execution. First, align early development programs with clear biomarker strategies and companion diagnostic plans to increase the probability of regulatory success and payer acceptance; integrating diagnostic development into pivotal trials reduces downstream barriers to access. Second, prioritize supply chain redundancy for critical biologic components and finished products, including dual-sourcing, regional manufacturing options, and validated contingency plans to mitigate tariff-driven disruptions and logistic volatility.
Third, design commercial models that reflect route-of-administration preferences and distribution realities, investing in hub-and-spoke service models that support hospital-administered infusions while enabling retail access for oral maintenance therapies. Fourth, invest in robust real-world evidence generation to demonstrate long-term value and to support innovative contracting models with payers, including outcomes-based agreements where feasible. Fifth, actively pursue strategic partnerships-whether licensing, co-development, or manufacturing alliances-to accelerate development timelines and broaden market reach while sharing commercial risk. By implementing these actions in a coordinated manner, leaders can improve launch readiness, optimize ROI on development investments, and enhance patient access to transformative therapies.
A rigorous mixed-methods approach combining expert interviews, literature synthesis and data triangulation to produce validated and actionable intelligence
The research methodology underpinning this executive summary combines qualitative expert insight with systematic synthesis of primary and secondary inputs to ensure robust, actionable conclusions. Primary research consisted of structured interviews with oncologists, clinical trial investigators, regulatory affairs specialists, payers, and supply chain leaders engaged in gastric cancer therapeutics; these interviews provided contemporary perspectives on clinical adoption patterns, reimbursement expectations, and operational constraints. Secondary research incorporated peer-reviewed literature, regulatory guidance documents, clinical trial registries, and established therapeutic guidelines to validate mechanistic understandings and to contextualize trial outcomes and approval precedents.
Data triangulation was applied to reconcile divergent views across stakeholders and to identify consistent themes that merit strategic attention. Where possible, case examples from recent approvals and payer decisions were used to illustrate practical implications for commercialization and evidence generation, without relying on proprietary market estimates. The synthesis emphasized cross-functional alignment-linking clinical trial design to diagnostic strategy, manufacturing strategy, and payer engagement-to provide a holistic framework that organizations can operationalize. Finally, quality assurance procedures, including expert review and iterative validation with clinical advisors, were employed to ensure the accuracy and relevance of the findings presented here.
A concise synthesis of pivotal scientific, operational and market imperatives that will determine which therapies realize their clinical and commercial potential in gastric cancer
In summary, the gastric cancer therapeutic arena is transitioning into an era defined by precision approaches, more complex combination strategies, and heightened expectations for demonstrable value. Scientific advances are expanding treatment options, especially for biomarker-defined subgroups, while commercial success will increasingly depend on early integration of diagnostic strategies, resilient supply chains, and compelling real-world evidence to support reimbursement. Trade and policy developments, including tariff adjustments, have highlighted the need for geographic diversification of manufacturing and flexible sourcing to preserve clinical supply and launch timelines.
Looking ahead, organizations that invest in biomarker-driven development, cultivate strategic partnerships, and proactively engage payers with rigorous outcomes data will be best positioned to translate clinical innovation into sustained patient impact. The path to durable success in gastric oncology requires coordinated execution across R&D, regulatory affairs, manufacturing, and commercial functions, with an unwavering focus on meeting patient needs and demonstrating the value of new therapies in real-world settings.
Please Note: PDF & Excel + Online Access - 1 Year
Table of Contents
181 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency
- 1.5. Language
- 1.6. Stakeholders
- 2. Research Methodology
- 3. Executive Summary
- 4. Market Overview
- 5. Market Insights
- 5.1. FDA approval of FGFR2b-targeted monoclonal antibodies driving precision medicine in gastric cancer therapy
- 5.2. Rising adoption of PD-1/PD-L1 immune checkpoint inhibitors in first-line treatment protocols for advanced gastric cancer
- 5.3. Emergence of ctDNA-based liquid biopsy assays enabling real-time monitoring of treatment response in gastric cancer patients
- 5.4. Expansion of HER2-targeted tyrosine kinase inhibitors offering new first-line options for HER2-positive gastric tumors
- 5.5. Increased investment in bispecific antibody candidates addressing dual checkpoint pathways in gastric cancer immunotherapy
- 5.6. Growing focus on microbiome modulation therapies to enhance efficacy of standard chemotherapy regimens in gastric cancer
- 5.7. Strategic partnerships between biopharma and diagnostic firms to develop companion diagnostics for targeted gastric cancer drugs
- 5.8. Advancement of CAR-T cell therapies targeting Claudin 18.2 showing promising durable responses in refractory gastric cancer cases
- 6. Cumulative Impact of United States Tariffs 2025
- 7. Cumulative Impact of Artificial Intelligence 2025
- 8. Gastric Cancer Drugs Market, by Therapeutic Class
- 8.1. Biologics
- 8.1.1. Cytokines
- 8.1.2. Monoclonal Antibodies
- 8.2. Chemotherapy
- 8.2.1. Fluoropyrimidines
- 8.2.2. Platinum-Based Agents
- 8.2.3. Taxanes
- 8.3. Immunotherapy
- 8.3.1. Cancer Vaccines
- 8.3.2. Checkpoint Inhibitors
- 8.4. Targeted Therapy
- 8.4.1. Her2 Inhibitors
- 8.4.2. Vegf Inhibitors
- 9. Gastric Cancer Drugs Market, by Treatment Line
- 9.1. First Line
- 9.2. Second Line
- 9.3. Third Line Or Later
- 10. Gastric Cancer Drugs Market, by Route Of Administration
- 10.1. Intravenous
- 10.2. Oral
- 10.3. Subcutaneous
- 11. Gastric Cancer Drugs Market, by Dosage Form
- 11.1. Capsules
- 11.2. Lyophilized Powder
- 11.3. Pre-Filled Syringe
- 11.4. Tablets
- 12. Gastric Cancer Drugs Market, by Therapy Type
- 12.1. Combination Therapy
- 12.2. Monotherapy
- 13. Gastric Cancer Drugs Market, by Distribution Channel
- 13.1. Hospital Pharmacies
- 13.2. Retail Pharmacies
- 14. Gastric Cancer Drugs Market, by Region
- 14.1. Americas
- 14.1.1. North America
- 14.1.2. Latin America
- 14.2. Europe, Middle East & Africa
- 14.2.1. Europe
- 14.2.2. Middle East
- 14.2.3. Africa
- 14.3. Asia-Pacific
- 15. Gastric Cancer Drugs Market, by Group
- 15.1. ASEAN
- 15.2. GCC
- 15.3. European Union
- 15.4. BRICS
- 15.5. G7
- 15.6. NATO
- 16. Gastric Cancer Drugs Market, by Country
- 16.1. United States
- 16.2. Canada
- 16.3. Mexico
- 16.4. Brazil
- 16.5. United Kingdom
- 16.6. Germany
- 16.7. France
- 16.8. Russia
- 16.9. Italy
- 16.10. Spain
- 16.11. China
- 16.12. India
- 16.13. Japan
- 16.14. Australia
- 16.15. South Korea
- 17. Competitive Landscape
- 17.1. Market Share Analysis, 2024
- 17.2. FPNV Positioning Matrix, 2024
- 17.3. Competitive Analysis
- 17.3.1. AbbVie Inc.
- 17.3.2. Amgen Inc.
- 17.3.3. Astellas Pharma Inc.
- 17.3.4. AstraZeneca PLC
- 17.3.5. Bayer AG
- 17.3.6. Biogen MA Inc.
- 17.3.7. Boehringer Ingelheim GmbH
- 17.3.8. Bristol-Myers Squibb Company
- 17.3.9. Cipla Limited
- 17.3.10. Eli Lilly and Company
- 17.3.11. F. Hofmann-La Roche Ltd.
- 17.3.12. Gilead Sciences, Inc.
- 17.3.13. GlaxoSmithKline PLC
- 17.3.14. Incyte Corporation
- 17.3.15. Ipsen Pharma
- 17.3.16. Johnson & Johnson Services, Inc.
- 17.3.17. Mallinckrodt PLC
- 17.3.18. Merck KGaA
- 17.3.19. Novartis AG
- 17.3.20. Pfizer, Inc.
- 17.3.21. Regeneron Pharmaceuticals, Inc.
- 17.3.22. Sanofi Group
- 17.3.23. Sumitomo Pharma Co., Ltd.
- 17.3.24. Sun Pharmaceuticals Limited
- 17.3.25. Takeda Pharmaceutical Company Limited
- 17.3.26. Teva Pharmaceutical Industries Ltd.
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
